Clinical Trial Update: A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) [Phase 1, Phase 2]

View source ↗

Summary

A randomized placebo-controlled multicenter study evaluating JTR-161, an allogeneic human dental pulp stem cell, for acute ischemic stroke (J-REPAIR) has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• JTR-161

Snippet

Sponsor: Teijin Pharma Limited | Conditions: Acute Ischemic Stroke | Phase 1, Phase 2 | Status: COMPLETED